UnitedHealth Group (UNH) has been closely watched by the market over the past year due to multiple factors. On one hand, the company faces regulatory and legal pressures; on the other hand, its stock has attracted active buying from prominent investors such as Warren Buffett and Michael Burry, indicating market recognition of the company’s long-term value.
In February of this year, the U.S. Department of Justice launched criminal and civil investigations into UnitedHealth’s Medicare Advantage program, questioning whether it may have manipulated diagnosis coding to inflate patient risk scores, thereby obtaining excess government reimbursements. Prior to this, in December, the federal Medicare program had paid the company billions of dollars, some of which were disputed. Additionally, the Justice Department filed a lawsuit on antitrust grounds, seeking to block UnitedHealth’s acquisition of home health service provider Amedisys.
Beyond regulatory risks, the company also encountered an incident that drew widespread public attention: at the end of 2024, Brian Thompson, then-CEO of its insurance division, was killed in New York. While this tragedy should have evoked sympathy, it instead sparked extensive criticism of the U.S. healthcare system on social media, reflecting public dissatisfaction with the healthcare system.
In terms of performance, UnitedHealth’s recent quarterly earnings reports have consistently fallen short of investor expectations. In May of this year, the company announced a downward revision of its fiscal year guidance, causing its stock price to plummet 27% in a single day. This was followed by significant management changes, with former Chairman Stephen Hemsley replacing Andrew Witty as CEO. The company also withdrew its previously issued 2025 performance guidance, further increasing market uncertainty.
Despite these challenges, many prominent investors remain optimistic about its long-term value. Berkshire Hathaway, led by Warren Buffett, newly acquired over 5 million shares in the second quarter, with an end-of-period market value of approximately $1.57 billion. Meanwhile, Renaissance Technologies increased its holdings by 1.35 million shares, Appaloosa by 2.3 million shares, and Dodge & Cox by 4.73 million shares. Michael Burry and the Saudi Public Investment Fund (PIF) also purchased call options on the company.
Another key reason for the market’s optimism toward UnitedHealth lies in the company’s advantageous position amid demographic changes in the United States. The country continues to face an accelerating aging population: in 2022, the population aged 65 and above reached 58 million, accounting for 17% of the total population. By 2025, this proportion is expected to rise to 19%, and by 2030, it will exceed 21%, with a scale of over 71 million people. By 2065, the elderly population is projected to reach 25%. This trend implies sustained growth in healthcare demand, and as the primary group covered by insurance, the elderly will drive the expansion of the health insurance market.
As the largest health insurance company in the United States, UnitedHealth is poised to benefit significantly from this irreversible demographic shift. Although market competition may intensify as a result, its leading market share and industry position remain difficult to challenge. Against the backdrop of structural growth, the company continues to possess long-term investment value.
